{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:56:00Z","timestamp":1790672160795,"version":"4.1.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Infantile hemangiomas are the most common vascular tumor of infancy. Treatment of infantile hemangiomas was revolutionized when propranolol, a nonselective \u03b2-blocker, was reported to be effective therapy. In this review, we highlight the lessons learned using propranolol to treat infantile hemangiomas. We also describe the ongoing effort to understand the mechanism of action of propranolol.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Although the pathogenesis of infantile hemangiomas is not fully understood, maternal hypoxic stress and embolization of placental tissue are suggested to be critical components in their development. The mechanism of action of propranolol remains unclear, however various molecular mechanisms are detailed in this review. Propranolol treatment remains a well tolerated therapy, with low risk of adverse events or long-term neurocognitive effects. Dosing recommendations and optimal treatment duration vary among studies, and should be altered in patients with certain medical conditions such as Posterior fossa anomalies, Hemangioma, Arterial lesions, Cardiac abnormalities\/coarctation of the aorta, Eye anomalies (PHACE) syndrome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Propranolol is a well tolerated and effective treatment for infantile hemangiomas. The efficacy of propranolol for infantile hemangiomas is clear, however questions pertaining to mechanism of action, pretreatment risk stratification, and optimal dosing remain unanswered. The guidelines for managing infantile hemangiomas with propranolol will continue to adapt as research catches up to clinical experience.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000000650","type":"journal-article","created":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T12:49:20Z","timestamp":1527252560000},"page":"499-504","source":"Crossref","is-referenced-by-count":31,"title":["Infantile hemangiomas: what have we learned from propranolol?"],"prefix":"10.1097","volume":"30","author":[{"given":"Rachael","family":"Hagen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Ghareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Zinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20240108","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1525-1470.2008.00626.x","article-title":"Infantile hemangiomas: how common are they? A systematic review of the medical literature","volume":"25","author":"Kilcline","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"R2-20240108","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy","volume":"358","author":"Leaute-Labreze","year":"2008","journal-title":"N Engl J Med"},{"key":"R3-20240108","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/bdr2.1023","article-title":"Infantile hemangiomas: an updated review on risk factors, pathogenesis, and treatment","volume":"109","author":"Smith","year":"2017","journal-title":"Birth Defects Res"},{"key":"R4-20240108","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00403-016-1635-x","article-title":"Does hypoxia play a role in infantile hemangioma?","volume":"308","author":"De Jong","year":"2016","journal-title":"Arch Dermatol Res"},{"key":"R5-20240108","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/1076029617710333","article-title":"Circulating levels of vascular endothelial growth factor and basic fibroblastic growth factor in infantile hemangioma versus vascular malformations","volume":"24","author":"El-Raggal","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"R6-20240108","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jclinpath-2011-200191","article-title":"A placental chorionic villous mesenchymal core cellular origin for infantile haemangioma","volume":"64","author":"Itinteang","year":"2011","journal-title":"J Clin Pathol"},{"key":"R7-20240108","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93764","article-title":"NOTCH3 regulates stem-to-mural cell differentiation in infantile hemangioma","author":"Edwards","year":"2017","journal-title":"JCI Insight"},{"key":"R8-20240108","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.12659\/MSM.902374","article-title":"Mechanisms of action of microRNAs in infantile hemangioma tissue and vascular endothelial cells in different periods","volume":"23","author":"Chen","year":"2017","journal-title":"Med Sci Monit"},{"key":"R9-20240108","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.gene.2017.07.046","article-title":"microRNA-143 acts as a suppressor of hemangioma growth by targeting Bcl-2","volume":"628","author":"Huang","year":"2017","journal-title":"Gene"},{"key":"R10-20240108","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/apa.13684","article-title":"Neuropeptide Y receptor 1 is expressed by B and T lymphocytes and mast cells in infantile haemangiomas","volume":"106","author":"Tan","year":"2017","journal-title":"Acta Paediatr"},{"key":"R11-20240108","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1002\/jcb.26632","article-title":"Endogenous peptides profiles of human infantile hemangioma tissue and their clinical significance for treatment","volume":"119","author":"Li","year":"2018","journal-title":"J Cell Biochem"},{"key":"R12-20240108","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/j.ajpath.2017.05.014","article-title":"M1 macrophage-induced endothelial-to-mesenchymal transition promotes infantile hemangioma regression","volume":"187","author":"Wu","year":"2017","journal-title":"Am J Pathol"},{"key":"R13-20240108","doi-asserted-by":"crossref","first-page":"115817","DOI":"10.18632\/oncotarget.23705","article-title":"Over-expression of PPAR-\u03b32 gene enhances the adipogenic differentiation of hemangioma-derived mesenchymal stem cells in vitro and in vivo","volume":"8","author":"Yuan","year":"2017","journal-title":"Oncotarget"},{"key":"R14-20240108","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/pde.12781","article-title":"Infantile hemangiomas in twins: a prospective cohort study","volume":"33","author":"Greco","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"R15-20240108","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00000637-199703000-00014","article-title":"Hemangioma in twins","volume":"30","author":"Cheung","year":"1997","journal-title":"Ann Plast Surg"},{"key":"R16-20240108","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1525-1470.2012.01779.x","article-title":"Infantile hemangioma in four siblings","volume":"30","author":"Couto","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"R17-20240108","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/(SICI)1096-8628(19990101)82:1<77::AID-AJMG15>3.0.CO;2-A","article-title":"Genetic mapping of a novel familial form of infantile hemangioma","volume":"82","author":"Walter","year":"1999","journal-title":"Am J Med Genet"},{"key":"R18-20240108","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1542\/peds.2016-1623","article-title":"Inheritance patterns of infantile hemangioma","volume":"138","author":"Castr\u00e9n","year":"2016","journal-title":"Pediatrics"},{"key":"R19-20240108","first-page":"1185","article-title":"Infantile hemangioma: pathogenesis and mechanisms of action of propranolol","volume":"15","author":"Rotter","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"key":"R20-20240108","doi-asserted-by":"crossref","first-page":"e1060","DOI":"10.1542\/peds.2015-2485","article-title":"Diagnosis and management of infantile hemangioma","volume":"136","author":"Darrow","year":"2015","journal-title":"Pediatrics"},{"key":"R21-20240108","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bjd.13388","article-title":"The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action","volume":"172","author":"Ji","year":"2015","journal-title":"Br J Dermatol"},{"key":"R22-20240108","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.3892\/or.2015.3911","article-title":"Propranolol represses infantile hemangioma cell growth through the \u03b22-adrenergic receptor in a HIF-1\u03b1-dependent manner","volume":"33","author":"Li","year":"2015","journal-title":"Oncol Rep"},{"key":"R23-20240108","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.imlet.2017.03.005","article-title":"Molecular and immunohistochemical expression of apoptotic proteins Bax, Bcl-2 and Caspase 3 in infantile hemangioma tissues as an effect of propranolol treatment","volume":"185","author":"Wnek","year":"2017","journal-title":"Immunol Lett"},{"key":"R24-20240108","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/pr.2017.93","article-title":"The expression of renin\u2013angiotensin\u2013aldosterone axis components in infantile hemangioma tissue and the impact of propranolol treatment","volume":"82","author":"Dornhoffer","year":"2017","journal-title":"Pediatr Res"},{"key":"R25-20240108","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaad.2015.09.061","article-title":"Propranolol versus captopril in the treatment of infantile hemangioma (IH): a randomized controlled trial","volume":"74","author":"Zaher","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R26-20240108","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1136\/bjophthalmol-2015-307284","article-title":"Predicting complications with pretreatment testing in infantile haemangioma treated with oral propranolol","volume":"100","author":"Tang","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R27-20240108","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1080\/09546634.2016.1277177","article-title":"Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-h Holter monitoring in additional safety assessment","volume":"28","author":"Petrovic","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"R28-20240108","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamadermatol.2017.0250","article-title":"Comparison of efficacy and safety between propranolol and steroid for infantile hemangioma: a randomized clinical trial","volume":"153","author":"Kim","year":"2017","journal-title":"JAMA Dermatol"},{"key":"R29-20240108","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaad.2017.01.025","article-title":"Propranolol treatment of infantile hemangioma is not associated with psychological problems at 7 years of age","volume":"77","author":"Moyakine","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R30-20240108","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/1346-8138.13324","article-title":"Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas","volume":"43","author":"Hu","year":"2016","journal-title":"J Dermatol"},{"key":"R31-20240108","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaad.2016.02.1218","article-title":"Propranolol treatment of infantile hemangioma (IH) is not associated with developmental risk or growth impairment at age 4 years","volume":"75","author":"Moyakine","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R32-20240108","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/pde.13177","article-title":"Atenolol versus propranolol for treatment of infantile hemangiomas during the proliferative phase: a retrospective noninferiority study","volume":"34","author":"Bayart","year":"2017","journal-title":"Pediatr Dermatol"},{"key":"R33-20240108","doi-asserted-by":"crossref","first-page":"e20151754","DOI":"10.1542\/peds.2015-1754","article-title":"Rebound growth of infantile hemangiomas after propranolol therapy","volume":"137","author":"Shah","year":"2016","journal-title":"Pediatrics"},{"key":"R34-20240108","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/pr.2017.220","article-title":"Infantile hemangioma: factors causing recurrence after propranolol treatment","volume":"83","author":"Chang","year":"2018","journal-title":"Pediatr Res"},{"key":"R35-20240108","doi-asserted-by":"crossref","first-page":"e88856","DOI":"10.1172\/jci.insight.88856","article-title":"Endothelial and circulating C19MC microRNAs are biomarkers of infantile hemangioma","volume":"1","author":"Strub","year":"2016","journal-title":"JCI Insight"},{"key":"R36-20240108","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/ped.12981","article-title":"Propranolol for infantile hemangioma: effect on plasma vascular endothelial growth factor","volume":"58","author":"Ozeki","year":"2016","journal-title":"Pediatr Int"},{"key":"R37-20240108","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.imlet.2016.05.002","article-title":"Serum and tissue profile of VEGF and its receptors VGFR1\/R2 in children with infantile hemangiomas on systemic propranolol treatment","volume":"175","author":"Przewratil","year":"2016","journal-title":"Immunol Lett"},{"key":"R38-20240108","doi-asserted-by":"crossref","first-page":"43292","DOI":"10.1038\/srep43292","article-title":"When to stop propranolol for infantile hemangioma","volume":"7","author":"Chang","year":"2017","journal-title":"Sci Rep"},{"key":"R39-20240108","first-page":"30310","article-title":"Effect of oral propranolol on periocular capillary hemangiomas of infancy","volume":"16","author":"Koka","year":"2017","journal-title":"Pediatr Neonatol"},{"key":"R40-20240108","first-page":"205","article-title":"Infantile periocular hemangioma","volume":"12","author":"Tavakoli","year":"2017","journal-title":"J Ophthalmic Vis Res"},{"key":"R41-20240108","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.2147\/OPTH.S153121","article-title":"Combined oral propranolol with intralesional injection of triamcinolone acetonide in treatment of infantile periocular hemangiomas","volume":"11","author":"Alsmman","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"R42-20240108","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.otc.2017.09.009","article-title":"Infantile Hemangiomas in the head and neck region","volume":"51","author":"Adams","year":"2018","journal-title":"Otolaryngol Clin North Am"},{"key":"R43-20240108","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1111\/pde.12975","article-title":"Use of propranolol for treating hemangiomas in infants with previously diagnosed hypoglycemic conditions","volume":"33","author":"Yang","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"R44-20240108","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.otc.2017.09.001","article-title":"Management of infantile hemangiomas of the airway","volume":"51","author":"Darrow","year":"2018","journal-title":"Otolaryngol Clin North Am"},{"key":"R45-20240108","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jpeds.2016.07.054","article-title":"PHACE syndrome: consensus-derived diagnosis and care recommendations","volume":"178","author":"Garzon","year":"2016","journal-title":"J Pediatr"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008480-201808000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T09:04:53Z","timestamp":1704704693000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-201808000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000650","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}